Uncategorized

Clueless

Yesterday Medtronic acquired Klue who according to a story posted on Drug Delivery Business News is a as “software company that tracks people’s eating in real-time and analyzes it with artificial intelligence (AI) to help control diabetes.” The story goes onto state; “Medtronic plans to incorporate Klue’s technology into its Personalized Closed Loop (PCL) insulin pump system, which won FDA breakthrough device designation in February. PCL is designed to automate insulin...

The Cone of Silence

Today we’re going way back in the wave back machine referencing a very funny TV show Get Smart. Now for the millennials out there we highly recommend getting on YouTube or whatever streaming service you have and watching a few of what are truly hilarious episodes. One of the funniest scenes came when Max and the Chief went into the cone of silence and then in Get Smart fashion couldn’t...

The End is Near

With the approval of the Control IQ the last thing Sean Salmon the new guy running Medtronic diabetes needs is more bad news. But as Momma Kliff used to say this is why you earn the big bucks so put on your big boy pants and deal with it. Today Lilly and Dexcom reached a non-exclusive agreement to integrate Dexcom’s sensor into Lilly’s insulin delivery systems which include connected insulin...

The Rebels now have the Death Star

Finally this past Friday the FDA did what everyone expected and approved the Control IQ, creating lots of happy dancing for the folks at Tandem, not to mention the large and growing group of patients who were also anxiously awaiting its approval. Before we get into what this means a few quick thoughts. 1. Ok I know there is nothing we can do about this, but these Friday afternoon approvals have...

Are they in or out?

One of the bigger stories this week was Sanofi’s decision to basically exit diabetes, a decision that came a stunning admission that they “over-invested” in Onduo their joint venture with Verily. Yet days later comes word that the company has made an investment in the diabetes space. Per a press release issued yesterday; “ALCOR / Eligible PEA PME), a French company specializing in the development and manufacturing of medical devices and...

Is anyone paying attention?

Yesterday was just one of those days that makes us fully appreciate why we call this the wacky world of diabetes. As everyone now knows Sanofi says they “over-invested” in digital diabetes and therefore was stepping away from any active role in their partnership with Verily, Onduo. Naturally shares of Livongo increased on this news even though insiders have decided to start selling shares in mass which under normal circumstances...

“Over-Invested”

It’s a rare occasion when a CEO admits the company their running has made a mistake. Something that typically happens for one of two reasons, either they are set to retire or they are new to the job and can throw the CEO they replaced under the bus. Paul Hudson the new CEO at Sanofi became the bus driver yesterday when he said that Sanofi “over-invested” in Onduo their partnership...

Yep knew this was coming

Per a company issued press release; “Livongo Health, Inc. (LVGO) today announced plans for the commencement of an underwritten public offering of 2,777,327 shares of common stock by certain selling stockholders.” The release goes onto state; “In connection with the proposed offering, the selling stockholders, Livongo, and Livongo’s executive officers, directors and certain significant holders of its common stock including General Catalyst, Kinnevik, and 7Wire Ventures, have agreed, subject to certain exceptions, not...

The Fat Lady is singing

When we first heard the news that at long last Sanofi is calling it quits in diabetes, we had to check our calendar to make sure it wasn’t April Fool’s day. But nope it really is December 10, 2019 and yes at long last Sanofi is throwing in the towel, admitting defeat and moving onto hopefully greener pastures. This once mighty franchise which generated billions in profits is now just...

An Interesting Week

As the week winds down we’re wondering if when looked back upon five years from now will this week be seen as transition point. All week we’ve been following the social media and mainstream media firestorm over the technical issues Dexcom had with their sharing platform. Judging from the various Facebook posts and the visceral reaction from angry patients, parents, caregivers and some nutty conspiracy theorists one just might think...